Today: 21 May 2026
Browse Category

NYSE:SNY 16 September 2025 - 17 January 2026

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck & Co shares fell 1.9% to $108.83 Friday after a Reuters report highlighted industry concerns over the FDA’s new fast-track drug approval program. Internal FDA documents show some drug reviews have been delayed due to safety and effectiveness worries, including a patient death linked to Sanofi’s Tzield. The S&P 500 healthcare sector dropped 0.8% amid broader market weakness. Only one drug has been approved under the program so far.
17 January 2026
·····
Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares rose 0.3% to $25.67 Thursday as investors weighed U.S. vaccine policy debates and the company’s growth outlook. The stock moved between $25.26 and $25.67 with 22.3 million shares traded. Pfizer will report Q4 results on Feb. 3, with guidance projecting 2026 revenue of $59.5–$62.5 billion and lower COVID-19 product sales. Competition in obesity drugs and AI-driven drug discovery remain in focus.
15 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer shares fell 0.6% to $25.42 in late-morning trading Thursday as U.S. vaccine policy changes fueled uncertainty. Sanofi warned of weaker U.S. vaccine demand; Pfizer’s CEO criticized the new recommendations. Moderna and Merck also traded lower. Investors await Pfizer’s Feb. 3 results for updates on 2026 outlook and new product pipeline.
15 January 2026
········
Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Sanofi agreed to acquire Dynavax Technologies for $15.50 per share in cash, valuing the deal at about $2.2 billion. DVAX shares surged 39% to around $15.45, trading near the offer price after the announcement. Volume topped 30 million shares in a volatile session shortened for the holiday. The transaction is expected to close in Q1 2026, pending customary conditions.
24 December 2025
··
Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Dynavax Technologies (DVAX) Stock Jumps on Sanofi’s $2.2B Cash Buyout Offer: Latest News, Forecasts, and What Comes Next (Dec. 24, 2025)

Sanofi announced a deal to acquire Dynavax Technologies for $2.2 billion in cash, offering $15.50 per share—a 39% premium to Dynavax’s prior close. DVAX stock jumped about 37% premarket to near the offer price. Dynavax’s board approved the transaction. Closing is expected in Q1 2026, pending regulatory and shareholder approvals.
24 December 2025
···
EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

EU Stock Markets Today (24 December 2025): STOXX 600 Flat on Christmas Eve as BP Castrol Deal, Sanofi’s Dynavax Move and Record Metals Set the Tone

The STOXX 600 index was flat at 588.93 by 08:09 GMT on December 24, 2025, as EU stock markets saw sharply reduced liquidity with Germany and Italy closed and other exchanges running shortened sessions for Christmas Eve. Energy shares rose on firmer oil, while miners tracked gains in precious metals. Trading volumes were thin across the continent.
24 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

President Trump and nine major drugmakers announced deals on Dec. 19 to cut Medicaid and cash-pay drug prices, shifting U.S. pharma policy focus. Shares of most participating firms rose 1%–3%. Trading in the week of Dec. 22–26 is expected to be volatile due to thin holiday liquidity and headline sensitivity. U.S. markets will close early Dec. 24 and remain shut Dec. 25.
21 December 2025
·········
Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

President Donald Trump and nine major drugmakers announced deals to cut U.S. drug prices for Medicaid and cash-paying patients, with discounts up to 70% off list prices and a three-year tariff reprieve. Shares of several companies rose modestly after the news. Commitments include free Eliquis for Medicaid and steep discounts on diabetes and migraine drugs. The moves reshape investor expectations for healthcare stocks heading into 2026.
20 December 2025
········
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly will invest $5 billion to build a 200,000-square-foot drug manufacturing plant in Goochland County, Virginia, creating 650 permanent jobs and 1,800 construction jobs. The facility will produce active pharmaceutical ingredients for cancer and autoimmune treatments. The project is part of Lilly’s $27 billion U.S. expansion plan. Virginia approved over $10 million in incentives to secure the site.
16 September 2025
·······

Stock Market Today

  • Stocks Added to Zacks Strong Sell List May 21: AMTB, BP, COLM
    May 21, 2026, 7:11 AM EDT. Amerant Bancorp Inc. (AMTB), BP p.l.c. (BP), and Columbia Sportswear Company (COLM) were added to the Zacks Rank #5 (Strong Sell) List on May 21. Each company has seen significant downward revisions in earnings estimates over the past 60 days: AMTB by 16.7%, BP by 22.4%, and COLM by 11.5%. The Zacks Rank identifies stocks with expected underperformance. This follows Zacks' recommendation of semiconductor stocks benefiting from booming demand in AI, Machine Learning, and IoT, with semiconductor manufacturing projected to grow from $452 billion in 2021 to $803 billion by 2028. Investors can access free analysis reports and updated recommendations from Zacks Investment Research.

Latest articles

VIDA Global Stock Draws Attention After AI Agent IPO

VIDA Global Stock Draws Attention After AI Agent IPO

21 May 2026
VIDA Global shares jumped 81.2% to close at $4.15 Wednesday, then traded at $4.97 pre-market Thursday after volatile early sessions on NYSE American. Founder and CEO Lyle Pratt bought 187,500 shares at the $4 IPO price, SEC filings showed. The company raised $15 million in its IPO last week, selling 3.75 million shares. VIDA reported 2025 revenue of $551,383 and a net loss of $2.9 million.
Enphase shares climb 14% as Wall Street looks at solar stock again

Enphase shares climb 14% as Wall Street looks at solar stock again

21 May 2026
Enphase Energy shares jumped 13.7% to close at $53.15 Wednesday, just below last week’s 52-week high. Goldman Sachs raised its price target to $57 and maintained a Buy rating. Trading volume reached 11.1 million shares, well above the 50-day average. Enphase reported a 23% drop in U.S. first-quarter revenue and a 48% decline in sell-through demand from the prior quarter.
Plug Power’s UK hydrogen move may shake up PLUG shares but cash remains a risk

Plug Power’s UK hydrogen move may shake up PLUG shares but cash remains a risk

21 May 2026
Plug Power shares traded at $3.31, down 0.3% premarket Thursday, after announcing its UK Barrow Green Hydrogen project had reached final investment decision. The company will supply six 5 MW electrolyzers to the project, which aims to cut Kimberly-Clark’s Barrow plant gas use by up to 50%. Plug reported Q1 revenue up 22% to $163.5 million but posted a GAAP loss of 18 cents per share.
Go toTop